View in EDS HTML Full Text PDF Full Text

NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?

Saved in:
Bibliographic Details
Title: NSUNs-driven dysregulation: the next frontier in targeted cancer therapy?
Authors: Zhao Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Zhang Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Zhou H; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China., Zhang L; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Guo J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Tan Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Wu T; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Peng Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Che Y; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Pei Z; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Li J; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Fu B; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China., Wei M; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. mjwei@cmu.edu.cn.; Shenyang Kangwei Medical Laboratory Analysis Co. LTD, Liaoning Province, Shenyang, PR China. mjwei@cmu.edu.cn., Wu G; Hepatobiliary Surgery Department, First Hospital of China Medical University, Shenyang, Liaoning Province, PR China. gangw@cmu.edu.cn., Hu X; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. huxy2022@cmu.edu.cn., Wu H; Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Liaoning Key Laboratory of molecular targeted anti-tumor drug development and evaluation; Liaoning Cancer immune peptide drug Engineering Technology Research Center; China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.; Scientific experimental center, School of Pharmacy, China Medical University, Shenyang, PR China. wuhz@cmu.edu.cn.
Source: Cell death & disease [Cell Death Dis] 2025 Dec 18; Vol. 16 (1), pp. 901. Date of Electronic Publication: 2025 Dec 18.
Publication Type: Journal Article; Review
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:2041-4889
DOI:10.1038/s41419-025-08269-6